To Evaluate The Effect Of Ketoconazole, Ritonavir and Erythromycin on the Safety and Pharmacokinetics of Avanafil
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
This study is being conducted to examine the effect of three CYP3A4 inhibitors (ketoconazole,
erythromycin and ritonavir) on the single dose pharmacokinetics of avanafil. Ketoconazole and
ritonavir are potent inhibitors of CYP3A4 and erythromycin is a moderate CYP3A4 inhibitor.
Any interaction that is observed would be predictive of other inhibitors of CYP3A4.